Abstract: Nucleotide or base analogues having structure (3) or (4) wherein X═O or NH or S and each R6 is independently H or alkyl or alkenyl or alkoxy or aryl or a reporter moiety.

Abstract: The device and method for triggering a random event is suited for use as an RPG in a Packinko gaming machine and involves the use of a radioactive source and detector. Repeated measurement of decay events detected by the detector during selected time periods are compared against one another and preferably against a predetermined number and a win event is triggered when the numbers are equal. Appropriate selection of the predetermined number for comparison determines the probability of a win event being triggered. With this device and method materials having very low radioactivity may be used. Also, the device and method operates to trigger a win event at a desired probability without the need for the Mean output of the radioactive material to be measured accurately.

Abstract: A cyanine dye having the structure has an overall positive charge greater than +1, by virtue of the presence of one to five positively charged N or P or S atoms, and also has a reactive or functional group by which it may be linked to a biomolecule or a solid surface.

Abstract: A 99mTc complex which contains the moiety Tc═NR, Tc—N═NY or Tc(—N═NY)2, and as a synthetic organic ligand which confers biological target-seeking properties on the technetium complex, where: R is an aryl group, a substituted or unsubstituted alkyl group or the group —NR1R2; Y is an aryl group or a substituted or unsubstituted alkyl group; R1 and R2 are H, aryl groups or substituted or unsubstituted aliphatic or cyclic alkyl groups, and are the same or different provided that both are not hydrogen; where at least one of the R or Y groups comprises an aryl group which chelates the 99mTc.

Abstract: Tripodal chelating agents incorporating imine C.dbd.N bonds are disclosed for the formation of lanthanide and other metal complexes which are relatively stable in the presence of water at neutral pH.

Abstract: Additives are proposed for compositions comprising radiolabelled organic compounds e.g. 32P-labelled nucleotides. Stabilizers are selected from tryptophan, para-aminobenzoate, indoleacetate and the azole group. Dyes are selected from Sulphorhodamine B, Xylene Cyanol, Azocarmine B and New Coccine. Preferred compositions contain both stabilizer and dye.

Abstract: An improved brachytherapy seed having (a) a casing for encapsulating a radioactive material, wherein a center portion of the casing has a diameter that is substantially larger than the diameter of two end portions of the casing, and/or (b) a carrier for the radioisotope, wherein the carrier has a polygonal cross section, and, optionally, one end of the carrier is rotated around the longitudinal axis of the carrier.

Abstract: .sup.99m Tc complexes of formula L.sub.n Tc.dbd.NR, L.sub.n Tc--N.dbd.NY, or L.sub.n Tc--(N.dbd.NY).sub.2 wherein each L is independently a monodentate or multidentate ligand;Y is a substituted or unsubstituted aryl group or substituted or unsubstituted alkyl group;R is Y or the grouping --NR.sup.1 R.sup.2 ;n is 1-4;where at least one of R or Y is combined with one or more of the L groups; R.sup.1 and R.sup.2 are H, substituted or unsubstituted aryl groups or substituted or unsubstituted aliphatic or cyclic alkyl groups, and are the same or different, provided that both are not hydrogen.

Abstract: Ligands for radiopharmaceutical use are capable of chelating radiometal species and of being bound to biological targeting molecules. The ligands have formula (a) and (b), where A, A'=--SZ or Y, B.dbd.O or S, Y.dbd. (c), Z.dbd.H or a thiol protecting group, m=2 or 3, n=2 or 3, q=0 or 1, R.dbd.H or unsubstituted or substituted hydrocarbon and pharmaceutically acceptable salts, provided that at least one CR.sub.2 group represents CO and forms, together with an adjacent N atom, a --CONR-- amide group.

Abstract: A synth .sup.99m Tc complex which contains the moiety Tc.dbd.NR, Tc--N.dbd.NY or Tc(--N.dbd.NY).sub.2 and an organic ligand which confers biological target-seeking properties on the technetium complex, where R is an aryl group, a substituted or unsubstituted alkyl group or the group --NR.sup.1 R.sup.2 ; Y is an aryl group or a substituted or unsubstituted alkyl group; and R.sup.1 and R.sup.2 are H, aryl groups or substituted or unsubstituted aliphatic or cyclic alkyl groups, and are the same or different provided that both are not hydrogen. Radiopharmaceuticals comprising this complex are also described, together with methods for the preparation of the complex.

Abstract: Ligands for radiopharmaceutical use are capable of chelating radiometal species and of being bound to biological targeting molecules. The ligands have the formula (a) and (b), where A, A'=--SZ or Y, B=O or S, Y=(c), Z=H or a thiol protecting group, m=2 or 3, n=2 or 3, q=0 or 1, R=H or unsubstituted or substituted hydrocarbon and pharmaceutically acceptable salts, provided that at least one CR.sub.2 group represents CO and forms, together with an adjacent N atom; a --CONR-- amide group.

Abstract: Additives are proposed for compositions comprising radiolabelled organic compounds e.g. 32P-labelled nucleotides. Stabilisers are selected from tryptophan, para-aminobenzoate, indoleacetate and the azole group. Dyes are selected from Sulphorhodamine B, Xylene Cyanol, Azocarmine B and New Coccine. Preferred compositions contain both stabiliser and dye.

Abstract: A superconducting cyclotron is provided that includes a superconducting magnet. This superconducting magnet is arranged to provide a magnetic field that extends axially through a chamber which includes a radially extending beam space. There is further an interaction within the chamber between the axially extending magnetic field and RF energy that energizes particles that are circulating within the beam space. There is further a linear accelerator that is aligned with and exposed to the axially extending magnetic field of the superconducting cyclotron. The output of this linear accelerator communicates with an input to the beam space so that the particles for acceleration within the beam space are pre-accelerated by the linear accelerator.